Cue Biopharma is trading 5.2% down at $33.51 as the stock pulls back following a sharp multi-session rally triggered by its 1-for-30 reverse stock split.
- The move appears to be driven by profit-taking and natural volatility after the recent surge, as no new company-specific announcements or negative catalysts were identified.
- Broader markets are trading slightly higher, suggesting the decline is idiosyncratic to the stock's recent momentum rather than a market-wide selloff.
- No significant news regarding earnings, FDA updates, or corporate deals was reported for the July 09, 2026, session.